StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SANGINITA.NS$29.19+2.00%
Fair $29.19+0.0%

SANGINITA.NS

Sanginita Chemicals Limited

Basic Materials / ChemicalsNSE

$29.19

+0.56 (+2.00%)

Fairly Valued+0.0%Fair Value $29.19Fund rank 25/100 · Data gapFallback financials|
SA 45/C
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-59.2M · quality 43.7/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 8/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

45/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. ROE is -20.9%, below the 5% threshold
Thesis & Journal · SANGINITA.NSLocal privado en este navegador · Sanginita Chemicals Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$756M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-20.9%

↓

Gross Margin

-2.0%

↓

Debt/Equity

0.26

↑
52-Week Range$29
$9$29

TradingView lightweight chart

SANGINITA.NS price, volumen y niveles de valoración

Último $28.62Periodo +42.2%
Fair value: $29.19

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+5.9%

FCF CAGR

+6.0%

FCF margin

8.7%

FCF / Net income

-1.58x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.76B · net income $-96.9M · FCF $152.8M

2023-FY → 2026-FY

Gross margin

-2.0%-6.6% pts

Operating margin

-4.6%-6.3% pts

Net margin

-5.5%-5.8% pts

FCF margin

8.7%+0.0% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$1.76B$1.76B$2.30B$1.52B$1.49B
Net Income$-96.9M$-96.9M$6.2M$7.7M$4.2M
EBITDA$-56.1M$-56.1M$49.4M$44.0M$35.2M
EPS——0.240.410.22
Gross Margin-2.0%-2.0%3.6%4.7%4.5%
Operating Margin-4.6%-4.6%1.3%2.1%1.7%
Net Margin-5.5%-5.5%0.3%0.5%0.3%
Balance Sheet
Debt/Equity0.260.260.470.810.71
Current Ratio2.372.37———
Cash Flow
Free Cash Flow$152.8M$152.8M$-59.2M$-62.0M$128.1M
Returns
ROE-20.9%-20.9%1.1%1.9%1.0%
Valuation
P/E——50.4655.0083.75
EV/EBITDA——11.6517.1917.98
P/B1.631.630.561.050.86
Growth & Yield
Revenue Growth-23.2%-23.2%51.6%2.0%—
EPS Growth——-41.1%87.5%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +170.3%

Total return

+170.3%

Start / end P/E

n/dx → n/dx

EPS bridge

0.24 → n/d

Residual

+170.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+170.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.